ATE353891T1 - Ditosylatsalze von chinazolinverbindungen - Google Patents

Ditosylatsalze von chinazolinverbindungen

Info

Publication number
ATE353891T1
ATE353891T1 AT01952304T AT01952304T ATE353891T1 AT E353891 T1 ATE353891 T1 AT E353891T1 AT 01952304 T AT01952304 T AT 01952304T AT 01952304 T AT01952304 T AT 01952304T AT E353891 T1 ATE353891 T1 AT E353891T1
Authority
AT
Austria
Prior art keywords
chinazoline
compounds
ditosylate salts
ditosylate
salts
Prior art date
Application number
AT01952304T
Other languages
English (en)
Inventor
Michael S Mcclure
Martin H Osterhout
Frank Roschangar
Mark J Sacchetti
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26910112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE353891(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE353891T1 publication Critical patent/ATE353891T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01952304T 2000-06-30 2001-06-28 Ditosylatsalze von chinazolinverbindungen ATE353891T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21550800P 2000-06-30 2000-06-30
US27184501P 2001-02-27 2001-02-27

Publications (1)

Publication Number Publication Date
ATE353891T1 true ATE353891T1 (de) 2007-03-15

Family

ID=26910112

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01952304T ATE353891T1 (de) 2000-06-30 2001-06-28 Ditosylatsalze von chinazolinverbindungen

Country Status (25)

Country Link
US (2) US7157466B2 (de)
EP (1) EP1294715B1 (de)
JP (2) JP4102185B2 (de)
KR (2) KR100815681B1 (de)
CN (2) CN1305872C (de)
AR (1) AR031248A1 (de)
AT (1) ATE353891T1 (de)
AU (3) AU2001273071B2 (de)
BR (1) BR0111947A (de)
CA (1) CA2413134C (de)
CY (1) CY1107054T1 (de)
CZ (2) CZ300945B6 (de)
DE (1) DE60126611T2 (de)
DK (1) DK1294715T3 (de)
ES (1) ES2280382T3 (de)
HU (1) HU229624B1 (de)
IL (3) IL153111A0 (de)
MX (1) MXPA02012681A (de)
MY (1) MY133667A (de)
NO (2) NO324637B1 (de)
NZ (1) NZ522989A (de)
PL (1) PL204958B1 (de)
PT (1) PT1294715E (de)
TW (2) TW200914443A (de)
WO (1) WO2002002552A1 (de)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
PL359920A1 (en) * 2000-09-20 2004-09-06 Merck Patent Gmbh 4-amino-quinazolines
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
AU2003251010A1 (en) 2002-07-15 2004-02-02 Janssen Pharmaceutica N.V. 3-furanyl analogs of toxoflavine as kinase inhibitors
US20060122240A1 (en) * 2002-11-05 2006-06-08 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
EP1622587B1 (de) * 2003-05-02 2010-04-28 Globopharm Pharmazeutische Produktions- und Handelsgesellschaft m.b.H. Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze
CN1805938B (zh) 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
MXPA05013365A (es) * 2003-06-20 2006-04-05 Arena Pharm Inc Derivados de n-fenil-piperazina y metodos para profilaxis o tratamiento de enfermedades asociadas con el receptor 5ht2c.
WO2005011607A2 (en) 2003-08-01 2005-02-10 Smithkline Beecham Corporation Treatment of cancers expressing p95 erbb2
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
JP4828421B2 (ja) * 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
AU2004298448B2 (en) * 2003-12-18 2010-09-09 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
BRPI0511754A (pt) * 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
MXPA06013952A (es) * 2004-06-04 2007-02-08 Smithkline Beecham Cork Ltd Metodo para el tratamiento de cancer.
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
US20080125428A1 (en) * 2004-08-27 2008-05-29 David Rusnak Cancer Treatment Method
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
NZ589951A (en) * 2004-12-23 2012-11-30 Arena Pharm Inc 5HT2C receptor modulator compositions and methods of use
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR101356748B1 (ko) 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US20090203718A1 (en) * 2006-04-13 2009-08-13 Smithkline Beecham (Cork) Ltd. Cancer treatment method
MX2008013430A (es) 2006-04-19 2009-01-26 Novartis Vaccines & Diagnostic Compuestos de indazol y metodos para la inhibición de cdc7.
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
KR20090090336A (ko) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
CN101245050A (zh) * 2007-02-14 2008-08-20 上海艾力斯医药科技有限公司 4-苯胺喹唑啉衍生物的盐
WO2008154469A1 (en) * 2007-06-11 2008-12-18 Smithkline Beecham (Cork) Limited Quinazoline salt compounds
JP2010540459A (ja) * 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． Ｃｏｘ‐２阻害薬及びｅｇｆｒ［ｅｒｂｂ１］とｈｅｒ‐２［ｅｒｂｂ２］の二重阻害薬を用いた癌を治療するための併用療法
WO2009079541A1 (en) * 2007-12-18 2009-06-25 Smithkline Beecham (Cork) Limited Quinazoline ditosylate anhydrate forms
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
US8822727B2 (en) * 2008-03-04 2014-09-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
JPWO2009113560A1 (ja) 2008-03-12 2011-07-21 武田薬品工業株式会社 縮合複素環化合物
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
US20120035183A1 (en) * 2008-03-19 2012-02-09 Gilmer Tona M Cancer Treatment Method
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
WO2010017387A2 (en) * 2008-08-06 2010-02-11 Teva Pharmaceutical Industries Ltd. Lapatinib intermediates
EP2158912A1 (de) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit N-[3-chlor-4-(3-fluorophenyl)methoxy)phenyl)6-(5(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furyl)-4-chinazolinamin
EP2158913A1 (de) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit N-[3-chlor-4-(3-fluorophenyl)methoxy)phenyl)6-(5(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furyl)-4-chinazolinamin
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
WO2010061400A1 (en) * 2008-11-03 2010-06-03 Natco Pharma Limited A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts
CN101735200B (zh) * 2008-11-17 2013-01-02 岑均达 喹唑啉类化合物
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
EA027959B1 (ru) 2009-08-21 2017-09-29 Смитклайн Бичем (Корк) Лтд. Способ лечения рака с помощью лапатиниба
EP2484678B1 (de) 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituierte anilin-)chinazolinderivate als tyrosinkinasehemmer
WO2011039759A1 (en) * 2009-09-29 2011-04-07 Natco Pharma Limited A new process for the preparation of lapatinib and its pharmaceutically acceptable salts
CN102079759B (zh) * 2009-12-01 2014-09-17 天津药物研究院 6位取代的喹唑啉类衍生物、其制备方法和用途
WO2011069074A2 (en) 2009-12-04 2011-06-09 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
JP2013519719A (ja) 2010-02-18 2013-05-30 セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ） トリアゾロ［４，５−ｂ］ピリジン誘導体
EP2550269B1 (de) 2010-03-23 2016-03-23 Scinopharm Taiwan Ltd. Verfahren und zwischenprodukte zur herstellung von lapatinib
US8710221B2 (en) 2010-03-23 2014-04-29 Scinopharm Taiwan, Ltd. Process and intermediates for preparing lapatinib
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
WO2011130831A1 (en) * 2010-04-22 2011-10-27 Apotex Pharmachem Inc. Polymorphic forms of lapatinib ditosylate and processes for their preparation
US20130072507A1 (en) 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
JP5858989B2 (ja) 2010-05-21 2016-02-10 ノバルティス アーゲー 組合せ
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
WO2011153206A1 (en) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
CN102295638B (zh) * 2010-06-24 2014-07-09 齐鲁制药有限公司 拉帕替尼的制备方法
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US20130131090A1 (en) * 2010-08-03 2013-05-23 Bandi Parthasaradhi Reddy Salts of lapatinib
EA201390335A1 (ru) 2010-09-01 2013-09-30 Арена Фармасьютикалз, Инк. Введение лоркасерина индивидуумам с почечной недостаточностью
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
KR20130101524A (ko) 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
EP2655364A4 (de) 2010-12-23 2014-06-11 Apotex Pharmachem Inc Verfahren zur herstellung von lapatinib und seinem ditosylatsalz
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
EP2680850B1 (de) 2011-03-04 2018-05-23 Newgen Therapeutics, Inc. Alkynsubstituierte chinazolinverbindung und verfahren zu ihrer verwendung
CN103648500B (zh) 2011-03-17 2016-05-04 宾夕法尼亚大学理事会 双功能酶制钳型分子的方法和用途
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
ITMI20110480A1 (it) 2011-03-25 2012-09-26 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di lapatinib e suoi sali
FI2694072T4 (fi) 2011-04-01 2024-09-30 Genentech Inc Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
CN102918029B (zh) * 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
AU2012257513B2 (en) 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
EP2524918A1 (de) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazinderivate als Kinase Inhibitoren
ITMI20110894A1 (it) 2011-05-20 2012-11-21 Italiana Sint Spa Impurezza del lapatinib e suoi sali
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
CN102321076B (zh) * 2011-07-07 2013-08-21 中国科学技术大学 拉帕替尼中间体及其类似物的制备方法
SG11201401716XA (en) 2011-10-28 2014-05-29 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013080218A1 (en) 2011-11-28 2013-06-06 Fresenius Kabi Oncology Ltd. Novel intermediates and process for the preparation of lapatinib and its pharmaceutically acceptable salts
BR112014019034A8 (pt) 2012-01-31 2017-07-11 Smithkline Beecham Cork Ltd Método para tratamento de câncer
CN105566305B (zh) * 2012-03-06 2018-08-14 齐鲁制药有限公司 4-(取代苯胺基)喹唑啉衍生物二甲苯磺酸盐的多晶型物及其制备方法和用途
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
CN104349779A (zh) 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
RU2674670C1 (ru) 2012-10-09 2018-12-12 Арена Фармасьютикалз, Инк. Способ коррекции массы тела
CZ2012712A3 (cs) 2012-10-17 2014-04-30 Zentiva, K.S. Nový způsob výroby klíčového intermediátu výroby lapatinibu
CN103819462B (zh) * 2012-11-19 2017-07-25 齐鲁制药有限公司 一种药用盐及其制备方法和用途
CN105732596B (zh) * 2012-11-19 2019-05-28 齐鲁制药有限公司 N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法
CN103819461B (zh) * 2012-11-19 2016-06-15 齐鲁制药有限公司 N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法
CN103896926A (zh) * 2012-12-27 2014-07-02 上海创诺医药集团有限公司 二对甲苯磺酸拉帕替尼溶剂化物多晶型物及其制法和用途
ITVI20130003A1 (it) 2013-01-14 2014-07-14 F I S Fabbrica Italiana Sint I S P A Procedimento per la preparazione di lapatinib e suoi sali mediante nuovi intermedi.
US9024023B2 (en) 2013-01-14 2015-05-05 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Efficient process for the preparation of lapatinib and salts thereof by means of new intermediates
EP2958552B1 (de) 2013-02-19 2017-06-21 Hexal AG Pharmazeutische zusammensetzung mit n-[3-chlor-4-(3-fluorbenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]chinazolin-4-amin oder ein pharmazeutisch akzeptables salz, solvat oder solvatisiertes salz daraus
CN103159747A (zh) * 2013-02-26 2013-06-19 常州鸿创高分子科技有限公司 一种二对甲苯磺酸拉帕替尼的合成方法
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
CN104098517A (zh) * 2013-04-09 2014-10-15 上海科胜药物研发有限公司 一种制备拉帕替尼中间体的方法
HU231012B1 (hu) 2013-05-24 2019-11-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Lapatinib sók
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
CN104788434A (zh) * 2014-01-16 2015-07-22 江苏恒瑞医药股份有限公司 一种蛋白酪氨酸激酶抑制剂的二苯磺酸盐
US20160361309A1 (en) 2014-02-26 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
EP2937346A1 (de) 2014-04-24 2015-10-28 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Co-Kristalle von Lapatinib
US20170252335A1 (en) 2014-10-17 2017-09-07 Novartis Ag Combination of Ceritinib with an EGFR Inhibitor
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EP3317323B1 (de) 2015-07-01 2021-05-26 California Institute of Technology Kationische schleimsäurepolymerbasierte abgabesysteme
JP6334065B2 (ja) 2015-07-29 2018-05-30 塩野義製薬株式会社 キナゾリン誘導体の塩またはその結晶およびそれらの製造方法
EP3331919A1 (de) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie mit anti-ctla-4-antikörpern
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
ES2913208T3 (es) 2015-12-01 2022-06-01 Glaxosmithkline Ip Dev Ltd Tratamientos de combinación y usos y métodos de los mismos
CN106892898B (zh) * 2015-12-18 2021-02-05 陕西师范大学 氮杂糖衍生化的喹唑啉类化合物
RU2603943C1 (ru) * 2016-02-01 2016-12-10 Индивидуальный предприниматель Михайлов Олег Ростиславович КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ N-{3-ХЛОР-4-[(3-ФТОРБЕНЗИЛ)ОКСИ] ФЕНИЛ}-6-[5-({[2-(МЕТАНСУЛЬФОНИЛ)ЭТИЛ]АМИНО}МЕТИЛ)-2-ФУРИЛ]-4-ХИНАЗОЛИНАМИНА БИС (4-МЕТИЛБЕНЗОЛСУЛЬФОНАТА) МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
EP3266773B1 (de) * 2016-07-04 2018-04-11 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Verfahren zur herstellung von lapatinib ditosylat monohydrat mittels eines verbesserten kristallisierungsprozesses
EP3494140A1 (de) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos- und anti-pd-1-antikörper-kombinationstherapie
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2018139626A1 (ja) 2017-01-30 2018-08-02 塩野義製薬株式会社 キナゾリン誘導体を含有する固形製剤
JP2021506974A (ja) 2017-12-18 2021-02-22 スターングリーン、インク． チロシンキナーゼ阻害剤として有用なピリミジン化合物
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
CN113795512A (zh) 2019-02-01 2021-12-14 葛兰素史克知识产权开发有限公司 包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法
CA3143211A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers
WO2021046293A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
EP4096718A1 (de) 2020-01-28 2022-12-07 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen und verwendungen und verfahren dafür
AU2021244786A1 (en) 2020-03-25 2022-11-03 Risen (Suzhou) Pharma Tech Co., Ltd. Stable heavy isotopes in amide functional groups and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (de) * 1994-11-12 1997-12-01 Zeneca Ltd
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AR007855A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze

Also Published As

Publication number Publication date
IL153111A0 (en) 2003-06-24
AU2010274106A1 (en) 2011-02-17
HUP0303022A3 (en) 2009-03-30
TWI307339B (en) 2009-03-11
HK1051041A1 (en) 2003-07-18
DE60126611D1 (de) 2007-03-29
MY133667A (en) 2007-11-30
KR100850393B1 (ko) 2008-08-04
JP2008050363A (ja) 2008-03-06
IL153111A (en) 2008-07-08
KR20030014414A (ko) 2003-02-17
NO20063572L (no) 2003-02-24
US7157466B2 (en) 2007-01-02
JP2004502687A (ja) 2004-01-29
BR0111947A (pt) 2003-05-06
WO2002002552A1 (en) 2002-01-10
US20030220354A1 (en) 2003-11-27
NO20026196L (no) 2003-02-24
KR20070100936A (ko) 2007-10-12
KR100815681B1 (ko) 2008-03-20
IL184115A0 (en) 2007-10-31
CA2413134C (en) 2010-05-11
TW200914443A (en) 2009-04-01
CN1440403A (zh) 2003-09-03
ES2280382T3 (es) 2007-09-16
HUP0303022A2 (hu) 2003-12-29
CN1636992A (zh) 2005-07-13
EP1294715A1 (de) 2003-03-26
NZ522989A (en) 2005-06-24
AU2001273071B2 (en) 2005-09-08
EP1294715B1 (de) 2007-02-14
CN1211382C (zh) 2005-07-20
NO20026196D0 (no) 2002-12-23
DE60126611T2 (de) 2007-11-22
NO324637B1 (no) 2007-11-26
JP4102185B2 (ja) 2008-06-18
US20080058519A1 (en) 2008-03-06
PT1294715E (pt) 2007-05-31
CN1305872C (zh) 2007-03-21
DK1294715T3 (da) 2007-06-04
PL204958B1 (pl) 2010-02-26
HU229624B1 (en) 2014-03-28
PL365637A1 (en) 2005-01-10
MXPA02012681A (es) 2003-04-25
CZ20024223A3 (cs) 2003-05-14
AU7307101A (en) 2002-01-14
CZ300945B6 (cs) 2009-09-23
AR031248A1 (es) 2003-09-17
CZ299561B6 (cs) 2008-09-03
CA2413134A1 (en) 2002-01-10
CY1107054T1 (el) 2012-10-24

Similar Documents

Publication Publication Date Title
DE60126611D1 (de) Ditosylatsalze von chinazolinverbindungen
DE60004317D1 (de) Salze von Sulfonium-Verbindungen
ATE411332T1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
EP1294513A4 (de) Lokalisationsspezifische kovalente biokonjugation von proteinen
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
DE60126814D1 (de) Inhalation von stickoxid
AR027983A1 (es) Novedosos compuestos
DE60127311D1 (de) Verbesserung von luftbleichkatalysatoren
DE60107074D1 (de) Kristallin form ii von cabergolin
NO20025659L (no) Heterocykliske forbindelser
NO20023954D0 (no) Substituerte piperasinforbindelser
NO20032255D0 (no) Dehalogen-forbindelser
AR028220A1 (es) Novedosos compuestos
DE60124282D1 (de) Leitweglenkung von kurznachrichten
NO20030303D0 (no) Kalsilytiske forbindelser
DE60031450D1 (de) Polymorph v von torasemid
DE60007360T2 (de) Amorphe modifikation von torasemid
NO20031837D0 (no) Kalsilytiske forbindelser
NO20023508L (no) Kalsilyttiske forbindelser
EE200100381A (et) Morfolinobensamiidi uued soolad
DE10197113T1 (de) Verbesserter spezieller Programmiermodus
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
AR028399A1 (es) Nuevos compuestos
DE60021925D1 (de) Flash-spinnen von polycyclopenten
DE60133605D1 (de) Ausrichten von Gegenständen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1294715

Country of ref document: EP